Thibault Mazard

3.3k total citations · 1 hit paper
90 papers, 1.8k citations indexed

About

Thibault Mazard is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Thibault Mazard has authored 90 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 69 papers in Oncology, 30 papers in Cancer Research and 25 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Thibault Mazard's work include Colorectal Cancer Treatments and Studies (40 papers), Cancer Genomics and Diagnostics (27 papers) and Genetic factors in colorectal cancer (18 papers). Thibault Mazard is often cited by papers focused on Colorectal Cancer Treatments and Studies (40 papers), Cancer Genomics and Diagnostics (27 papers) and Genetic factors in colorectal cancer (18 papers). Thibault Mazard collaborates with scholars based in France, United States and Spain. Thibault Mazard's co-authors include Eric Assénat, Laure Cayrefourcq, Catherine Alix‐Panabières, Alain R. Thierry, Thierry Maudelondé, Brice Pastor, Marc Ychou, Klaus Pantel, Cynthia Sánchez and Safia El Messaoudi and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer Research.

In The Last Decade

Thibault Mazard

80 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Blood contains circulating cell‐free respiratory competent mitochondria

2020 276 citations Zahra Al Amir Dache, Rita Tanos et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Thibault Mazard France	19	1.0k	863	570	400	376	90	1.8k
Iacopo Petrini Italy	27	1.0k 1.0×	688 0.8×	884 1.6×	723 1.8×	280 0.7×	91	2.5k
Akihiko Osaki Japan	23	747 0.7×	528 0.6×	529 0.9×	283 0.7×	155 0.4×	116	1.7k
Gert G. Van den Eynden Belgium	25	1.4k 1.4×	816 0.9×	939 1.6×	351 0.9×	195 0.5×	44	2.3k
Valentina Gambardella Spain	18	755 0.7×	485 0.6×	474 0.8×	471 1.2×	236 0.6×	85	1.5k
Anna Maria Rachiglio Italy	20	819 0.8×	607 0.7×	575 1.0×	544 1.4×	309 0.8×	43	1.5k
Xiaochun Fei China	27	874 0.8×	764 0.9×	634 1.1×	384 1.0×	407 1.1×	90	2.2k
Alessandro Bittoni Italy	23	935 0.9×	479 0.6×	437 0.8×	488 1.2×	158 0.4×	93	1.5k
Hao‐Xiang Wu China	22	596 0.6×	393 0.5×	520 0.9×	289 0.7×	162 0.4×	38	1.3k
Kate Cameron Netherlands	8	1.2k 1.2×	479 0.6×	1.0k 1.8×	197 0.5×	263 0.7×	14	2.0k
Junzhong Lin China	19	629 0.6×	572 0.7×	846 1.5×	311 0.8×	123 0.3×	64	1.7k

Countries citing papers authored by Thibault Mazard

Since Specialization

Citations

This map shows the geographic impact of Thibault Mazard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thibault Mazard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thibault Mazard more than expected).

Fields of papers citing papers by Thibault Mazard

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thibault Mazard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thibault Mazard. The network helps show where Thibault Mazard may publish in the future.

Co-authorship network of co-authors of Thibault Mazard

This figure shows the co-authorship network connecting the top 25 collaborators of Thibault Mazard. A scholar is included among the top collaborators of Thibault Mazard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thibault Mazard. Thibault Mazard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Taı̈eb, Julien, Margherita Ambrosini, Sara Lonardi, et al.. (2025). Early treatment discontinuation in patients with deficient mismatch repair or microsatellite instability high metastatic colorectal cancer receiving immune checkpoint inhibitors. Journal for ImmunoTherapy of Cancer. 13(1). e010424–e010424. 2 indexed citations

Tourneau, C. Le, C. Even, Assuntina G. Sacco, et al.. (2024). 411MO Petosemtamab (MCLA-158) monotherapy in previously treated (2L+) recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC): Phase II trial. Annals of Oncology. 35. S1557–S1558. 2 indexed citations

Adenis, Antoine, François Ghiringhelli, Thibault Mazard, et al.. (2024). Regorafenib plus FOLFIRINOX as first-line treatment for patients with RAS-mutant metastatic colorectal cancer (FOLFIRINOX-R trial): a dose-escalation study. Cancer Chemotherapy and Pharmacology. 94(3). 443–452. 1 indexed citations

Tougeron, David, Simon Pernot, Thibault Mazard, et al.. (2024). 143P Efficacy of immunotherapy in gastro-intestinal (GI) tumors with mismatch repair deficient (MMRd) unusual phenotype. Annals of Oncology. 35. S272–S272. 1 indexed citations

Fayette, Jérôme, Florian Clatot, Irene Braña, et al.. (2024). Petosemtamab (MCLA-158) with pembrolizumab as first-line (1L) treatment of recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC): Phase 2 study.. Journal of Clinical Oncology. 42(16_suppl). 6014–6014. 12 indexed citations

Gallois, Claire, Édouard Auclin, Elisabeth Bergen, et al.. (2023). 625P Efficacy and safety of the combination of encorafenib and cetuximab in patients with BRAF V600E mutated metastatic colorectal cancer: An AGEO real-world multicentre study. Annals of Oncology. 34. S446–S446. 4 indexed citations

Pilla, Lorenzo, Kathrin Heinrich, Volker Kunzmann, et al.. (2023). Efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient advanced pancreatic adenocarcinoma: An AGEO European Cohort.. Journal of Clinical Oncology. 41(16_suppl). 4148–4148.

Dache, Zahra Al Amir, et al.. (2022). Assessment of Dendrigrafts of Poly-l-lysine Cytotoxicity and Cell Penetration in Cancer Cells. ACS Applied Polymer Materials. 4(2). 908–919. 9 indexed citations

Quénet, François, Marta Jarlier, Sébastien Carrère, et al.. (2022). The desmoplastic growth pattern is associated with second-stage completion and longer survival in 2-stage hepatectomy for colorectal cancer liver metastases. Surgery. 172(5). 1434–1441.

10.

Taı̈eb, Julien, Valérie Taly, Julie Henriques, et al.. (2021). Prognostic Value and Relation with Adjuvant Treatment Duration of ctDNA in Stage III Colon Cancer: a Post Hoc Analysis of the PRODIGE-GERCOR IDEA-France Trial. Clinical Cancer Research. 27(20). 5638–5646. 71 indexed citations

11.

Folprecht, Gunnar, Erika Martinelli, Thibault Mazard, et al.. (2021). Triplet chemotherapy in combination with anti-EGFR agents for the treatment of metastatic colorectal cancer: Current evidence, advances, and future perspectives. Cancer Treatment Reviews. 102. 102301–102301. 13 indexed citations

12.

Assénat, Eric, Mohamed Bouattour, Louise Gauthier, et al.. (2021). 48P (BREGO) Regorafenib combined with modified m-GEMOX in patients with advanced biliary tract cancer (BTC): A phase II randomized trial. Annals of Oncology. 32. S376–S377. 4 indexed citations

13.

Sánchez, Cynthia, Benoît Roch, Thibault Mazard, et al.. (2021). Circulating nuclear DNA structural features, origins, and complete size profile revealed by fragmentomics. JCI Insight. 6(7). 56 indexed citations

14.

Assénat, Eric, Christelle de la Fouchardière, Marc Ychou, et al.. (2021). Sequential first-line treatment with nab-paclitaxel/gemcitabine and FOLFIRINOX in metastatic pancreatic adenocarcinoma: GABRINOX phase Ib-II controlled clinical trial. ESMO Open. 6(6). 100318–100318. 14 indexed citations

15.

Adenis, Antoine, et al.. (2020). Le protocole FLOT est-il le nouveau standard de chimiothérapie péri-opératoire des cancers de l’estomac ?. Bulletin du Cancer. 107(1). 54–60. 4 indexed citations

16.

Samalin, Emmanuelle, Thibault Mazard, Eric Assénat, et al.. (2019). Triplet chemotherapy plus cetuximab as first-line treatment in RAS wild-type metastatic colorectal carcinoma patients. Annals of Oncology. 30. iv26–iv27. 2 indexed citations

17.

Cayrefourcq, Laure, Thibault Mazard, Anna Babayan, et al.. (2018). Autologous cell lines from circulating colon cancer cells captured from sequential liquid biopsies as model to study therapy-driven tumor changes. Scientific Reports. 8(1). 15931–15931. 64 indexed citations

18.

Messaoudi, Safia El, Florent Moulière, Stanislas du Manoir, et al.. (2016). Circulating DNA as a Strong Multimarker Prognostic Tool for Metastatic Colorectal Cancer Patient Management Care. Clinical Cancer Research. 22(12). 3067–3077. 129 indexed citations

19.

Cayrefourcq, Laure, Thibault Mazard, Simon A. Joosse, et al.. (2015). Establishment and Characterization of a Cell Line from Human Circulating Colon Cancer Cells. Cancer Research. 75(5). 892–901. 284 indexed citations

20.

Morelli, Maria Pia, Michael J. Overman, Arvind Dasari, et al.. (2015). Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment. Annals of Oncology. 26(4). 731–736. 186 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact